Microcap Biotech Stock RenovoRx is Shooting Higher Today: Here's Why
Portfolio Pulse from Vandana Singh
RenovoRx Inc (NASDAQ:RNXT) presented new data from its Phase 3 TIGeR-PaC study of RenovoGem in advanced pancreatic cancer at the 2023 ESMO World Congress on Gastrointestinal Cancer. The interim analysis showed an eight-month median progression-free survival (PFS) benefit for patients treated with RenovoGem compared to standard care. The TIGeR-PaC Data Monitoring Committee found the interim data promising and recommended the continuation of the trial. RNXT shares are up 8.93% at $2.44.
June 29, 2023 | 6:09 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
RenovoRx's new data from its Phase 3 study of RenovoGem shows promising results, leading to a rise in its stock price.
The promising interim results from RenovoRx's Phase 3 study of RenovoGem in advanced pancreatic cancer have likely led to increased investor confidence, resulting in a rise in the company's stock price. The continuation of the trial also indicates potential future success, which could further boost the stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100